
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Salarius Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Merger
Salarius and Decoy Therapeutics Merge
Details : The proposed merger involves the development of a novel Peptide-drug Conjugate for respiratory infectious diseases.
Product Name : Undisclosed
Product Type : Peptide-drug Conjugate
Upfront Cash : Undisclosed
November 13, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Salarius Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Merger

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Decoy’s Inhibitors Show in Silico Activity Against Measles and Similar Viruses
Details : Antiviral drug candidates designed by its IMP3ACT platform are effective against viruses of the paramyxoviridae family also showed promising in silico activity against measles & Nipah viruses.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 26, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Deuterium Stabilized(S)-Avadomide
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Salarius Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Merger
Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement
Details : The combined company expects to accelerate development of respiratory & cancer products. In addition, the company intends to incorporate Salarius’ protein degrader SP-3164 for Non-Hodgkin’s Lymphomas.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 13, 2025
Lead Product(s) : Deuterium Stabilized(S)-Avadomide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Salarius Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Merger
